Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Elutia Inc

ELUT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$0.94

▲ +9.38%

Market Cap $41.60M · Vol 20.91K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$41.60M

Micro Cap

Div Yield

N/A

EPS Growth

-168.97%

YoY

RSI (14)

47.56

Momentum

Beta

0.88

vs Market

52W High

$2.48

62.06% below

52W Low

$0.50

87.26% above

Volume

20.91K

Avg 20.36K

P/B

1.07

Price-to-book

ROE

N/A

Return on equity

Free Float

80.75%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Elutia Inc (ELUT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ELUT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.71%

+3.18%

-9.52%

-10.38%

YTD

+35.85%

-56.23%

-34.20%

-88.24%

Financials & Valuation

TTM · Annual

Total Revenue	$12.29M
Net Income	$-15,871,000.00
Revenue Growth (YoY)	+5.52%
Gross Margin	53.66%
Operating Margin	-149.78%
Net Profit Margin	-129.11%
ROE	N/A
ROA · ROIC	-32.21% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.33
P/B	1.07
P/FCF	N/A
EPS Growth	-168.97%
Outstanding Shares	44.21M

Technical Indicators

50-Day SMA	$0.94
200-Day SMA	$0.94
RSI (14)	47.56
Beta	0.88
52-Week High	$2.48
52-Week Low	$0.50

Volume Today	20.91K
Avg Daily Volume (30D)	20.36K
Relative Volume	1.03x
Volatility (10D)	58.72
Volatility (30D)	51.82
Free Float	80.75%

Analyst Consensus

BUY

Current Price $0.94

Mean Target $5.00

52W Low$0.50 52W High$2.48

Current

Target

$0.50 $2.48

Current Analyst target

+431.35% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00BRBB847

ISINUS05479K1060

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.